GlobeNewswire

Solana Company Files Application to Cease to Be a Reporting Issuer in Canada
04/11/2025
NEWTOWN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (“ Solana ” or the “ Company ”) today announced that it has applied to the British Columbia Securities Commission, as principal regulator, [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Édition 2025 du congrès mondial du collectif médical polonais « Save a Life » : une mission d’envergure mondiale répondant à l’objectif de faire progresser l’expertise en sauvetage de vies
04/11/2025
Un rassemblement des professionnels de santé polonais répartis à travers le monde placé sous le signe de la coopération internationale et de l’excellence médicale VARSOVIE, Pologne, 04 nov. 2025 (GLOBE NEWSWIRE) -- Du [...]
Fueling Discovery: Misophonia Research Fund Launches New Team Science Award, Expands 2026 Funding Opportunities, and Announces Latest Grantee Cohort
04/11/2025
CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Misophonia Research Fund (MRF), an initiative of the REAM Foundation, announces a major expansion of its support of misophonia research – launching the first-ever team [...]
Chemed Corporation to Present at the UBS 2025 Global Healthcare Conference
04/11/2025
CINCINNATI, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at [...]
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
04/11/2025
– Mean weight loss of 19.2% I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data builds on previously reported Phase 2 results that showed mean weight loss of 23.6% I at 8 mg [...]
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
04/11/2025
Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistence SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit [...]
Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®
04/11/2025
First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus [...]
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
04/11/2025
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum